BIO-TECHNE Corp Financing Receivable, after Allowance for Credit Loss, Noncurrent
BIO-TECHNE Corp (TECH) had Financing Receivable, after Allowance for Credit Loss, Noncurrent of $7.56 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:NotesAndLoansReceivableNetNoncurrent · last filed 2026-08-24
- 2026-06-30: Financing Receivable, after Allowance for Credit Loss, Noncurrent $7.56M.
- 2026-03-31: Financing Receivable, after Allowance for Credit Loss, Noncurrent $8.12M.
- 2025-12-31: Financing Receivable, after Allowance for Credit Loss, Noncurrent $7.18M.
- 2025-09-30: Financing Receivable, after Allowance for Credit Loss, Noncurrent $7.74M.
| Period end | Financing Receivable, after Allowance for Credit Loss, Noncurrent |
|---|---|
| 2026-06-30 | $7.56M 10-K · filed 2026-08-24 |
| 2026-03-31 | $8.12M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $7.18M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $7.74M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.18M 10-K · filed 2026-08-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |